EMA Good clinical practice (GCP) inspection procedures

July 13, 2022

The Good Clinical Practice (GCP) Inspectors Working Group has developed procedures for the coordination, preparation, conduct and reporting of GCP inspections requested by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in the context of the centralised procedure.

These inspections are adopted by the CHMP and may be routine or may be triggered by issues arising during the assessment of the dossier or by other information such as previous inspection experience.

They are usually requested during the initial review of a marketing authorisation application, but could arise post-authorisation (e.g. inspection of studies conducted or completed as part of the condition of a marketing authorisation, or because of concerns arising about the studies previously submitted).

Guidance on remote inspections during COVID-19 pandemic

Guidance is available for inspectors on how to initiate and conduct remote inspections to verify compliance with GCP standards during the COVID-19 pandemic:

Guidance on remote GCP inspections during the COVID-19 pandemic

The guidance covers all phases of remote GCP inspections, with a particular focus on the more challenging aspects, such as inspection initiation, feasibility assessment and preparation.

EMA published the guidance on 10 June 2020.

Additional Inspection procedures and guidance

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.




EMA MAH

May 24, 2022

EMA post-authorisation procedural advice for users of the centralised procedure

This guidance document addresses a number of questions which marketing authorisation holders (MAHs) may have on post-authorisation procedures. It provides an overview of the Agency’s position on...

Read the Full Article
pesticides Europe

July 5, 2022

Draft report on the development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products, feed additives and pesticides in food of animal origin

In 2020, the European Commission (EC) requested EMA and European Food Safety Authority (EFSA) for advice for the development of a harmonised approach on exposure assessment methodologies for residues...

Read the Full Article
FDA EU

October 13, 2021

European Expedited Regulatory Programs Explained

Do you really know how to accelerate the approval of your innovative product in Europe?   European Expedited Regulatory Programs: The FDA’s incentives for promising new medicines are widely known....

Read the Full Article